Your browser doesn't support javascript.
loading
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Deng, Li-Juan; Zhou, Ke-Shu; Liu, Li-Hong; Zhang, Ming-Zhi; Li, Zhi-Ming; Ji, Chun-Yan; Xu, Wei; Liu, Ting; Xu, Bing; Wang, Xin; Gao, Su-Jun; Zhang, Hui-Lai; Hu, Yu; Li, Yan; Cheng, Ying; Yang, Hai-Yan; Cao, Jun-Ning; Zhu, Zun-Min; Hu, Jian-Da; Zhang, Wei; Jing, Hong-Mei; Ding, Kai-Yang; Zhang, Xiang-Yang; Zhao, Ren-Bin; Zhang, Bin; Tian, Ya-Min; Song, Yong-Ping; Song, Yu-Qin; Zhu, Jun.
Afiliação
  • Deng LJ; Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhou KS; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Liu LH; Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Zhang MZ; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li ZM; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine, Guangzhou, China.
  • Ji CY; Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
  • Xu W; Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
  • Liu T; Department of Hematology, West China Hospital of Sichuan University, Chengdu, China.
  • Xu B; Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
  • Wang X; Department of Hematology, Shandong Provincial Hospital, Jinan, China.
  • Gao SJ; Department of Hematology, The First Hospital of Jilin University, Changchun, China.
  • Zhang HL; Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • Hu Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Li Y; Department of Lymphoma, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Cheng Y; Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
  • Yang HY; Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China.
  • Cao JN; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Zhu ZM; Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou, China.
  • Hu JD; Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Zhang W; Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
  • Jing HM; Department of Hematology, Peking University Third Hospital, Beijing, China.
  • Ding KY; Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
  • Zhang XY; InnoCare Pharma Limited, Beijing, China.
  • Zhao RB; InnoCare Pharma Limited, Beijing, China.
  • Zhang B; InnoCare Pharma Limited, Beijing, China.
  • Tian YM; InnoCare Pharma Limited, Beijing, China.
  • Song YP; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Song YQ; Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhu J; Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
Blood Adv ; 7(16): 4349-4357, 2023 08 22.
Article em En | MEDLINE | ID: mdl-37078706
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombocitopenia / Linfoma de Célula do Manto / Neutropenia Tipo de estudo: Clinical_trials Limite: Adult / Humans / Middle aged Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombocitopenia / Linfoma de Célula do Manto / Neutropenia Tipo de estudo: Clinical_trials Limite: Adult / Humans / Middle aged Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article